Neogen Co. (NASDAQ:NEOG - Get Free Report) Director James C. Borel purchased 35,000 shares of the business's stock in a transaction on Thursday, April 24th. The stock was acquired at an average price of $4.89 per share, with a total value of $171,150.00. Following the completion of the acquisition, the director now directly owns 60,474 shares in the company, valued at $295,717.86. The trade was a 137.39 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Neogen Stock Up 5.7 %
Shares of NASDAQ NEOG opened at $5.20 on Friday. The stock has a market capitalization of $1.13 billion, a PE ratio of -2.37 and a beta of 1.57. The company has a quick ratio of 2.46, a current ratio of 3.77 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average of $8.11 and a 200-day moving average of $11.31. Neogen Co. has a 52-week low of $3.87 and a 52-week high of $18.58.
Neogen (NASDAQ:NEOG - Get Free Report) last posted its quarterly earnings results on Wednesday, April 9th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by ($0.02). The firm had revenue of $221.00 million for the quarter, compared to analysts' expectations of $225.27 million. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. Neogen's revenue was down 3.4% on a year-over-year basis. During the same period last year, the firm posted $0.12 EPS. On average, analysts anticipate that Neogen Co. will post 0.38 EPS for the current year.
Analysts Set New Price Targets
NEOG has been the subject of several analyst reports. Piper Sandler dropped their target price on Neogen from $6.40 to $5.00 and set a "neutral" rating for the company in a research note on Tuesday. Guggenheim lowered their price target on Neogen from $15.00 to $13.00 and set a "buy" rating for the company in a report on Thursday, April 10th.
Read Our Latest Stock Report on NEOG
Institutional Trading of Neogen
A number of institutional investors and hedge funds have recently bought and sold shares of NEOG. Barclays PLC grew its stake in Neogen by 129.8% during the third quarter. Barclays PLC now owns 366,753 shares of the company's stock worth $6,165,000 after buying an additional 207,160 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Neogen by 33.9% during the 3rd quarter. Franklin Resources Inc. now owns 923,918 shares of the company's stock valued at $15,531,000 after acquiring an additional 233,796 shares in the last quarter. Diversified Trust Co boosted its position in Neogen by 7.1% during the 4th quarter. Diversified Trust Co now owns 74,446 shares of the company's stock worth $904,000 after purchasing an additional 4,961 shares during the period. Harbor Capital Advisors Inc. increased its holdings in Neogen by 32.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,303,465 shares of the company's stock valued at $15,824,000 after purchasing an additional 316,457 shares in the last quarter. Finally, Procyon Advisors LLC raised its position in Neogen by 22.3% in the fourth quarter. Procyon Advisors LLC now owns 35,513 shares of the company's stock valued at $431,000 after purchasing an additional 6,467 shares during the period. Institutional investors and hedge funds own 96.73% of the company's stock.
Neogen Company Profile
(
Get Free Report)
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
